{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T05:31:51Z","timestamp":1787808711030,"version":"build-2784847793"},"reference-count":31,"publisher":"Cambridge University Press (CUP)","license":[{"start":{"date-parts":[[2018,8,5]],"date-time":"2018-08-05T00:00:00Z","timestamp":1533427200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"},{"start":{"date-parts":[[2018,8,5]],"date-time":"2018-08-05T00:00:00Z","timestamp":1533427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["europsy-journal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Eur. psychiatr."],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec id=\"S0924933800008841_abst0005\" sec-type=\"other\"><jats:title>Background:<\/jats:title><jats:p>The study aimed to investigate severe hair loss related to psychotropic drugs (PDs) by using data from the drug safety programme Arzneimittelsicherheit in der Psychiatrie (AMSP).<\/jats:p><\/jats:sec><jats:sec id=\"S0924933800008841_abst0010\" sec-type=\"methods\"><jats:title>Methods:<\/jats:title><jats:p>Data on PD utilization and reports of severe PD-related hair loss were collected in 83 psychiatric hospitals in Austria, Germany and Switzerland during the period 1993\u20132013.<\/jats:p><\/jats:sec><jats:sec id=\"S0924933800008841_abst0015\" sec-type=\"results\"><jats:title>Results:<\/jats:title><jats:p>Out of 432, 215 patients under surveillance, 404, 009 patients were treated with PDs for the main indications of depression, schizophrenic disorder, neurosis, mania, and organic psychosis. Severe hair loss related to PD treatment was reported in 43 cases (0.01%). The rates of hair loss under antipsychotic drugs were slightly lower than the mean rates of all PDs and antidepressant drugs. Valproic acid was related to the highest risk. In 6 of the 43 cases, hair loss was imputed to multiple drugs, with 4 cases imputed to double drug combinations and 2 cases to triple combinations. Rates of severe hair loss under valproic acid (VPA) and lithium salts were distinctly lower as compared with the overall rates reported in literature. Severe hair loss under PD treatment was reported significantly more often in female patients than in male patients (p &lt; 0.01).<\/jats:p><\/jats:sec><jats:sec id=\"S0924933800008841_abst0020\" sec-type=\"other\"><jats:title>Conclusion:<\/jats:title><jats:p>The rate of severe PD-related hair loss was very low in the present survey. The large number of patients included in this multicentre study allows for assessment and comparison of hair loss rates related to different PDs and groups of PDs and provides new and supplementary information on PD-related hair loss.<\/jats:p><\/jats:sec>","DOI":"10.1016\/j.eurpsy.2018.08.003","type":"journal-article","created":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T04:31:49Z","timestamp":1536121909000},"page":"117-123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Severe hair loss associated with psyc\nhotropic drugs in psychiatric inpatients\u2014Data from an observational pharmacovigilance program in German-speaking countries"],"prefix":"10.1017","volume":"54","author":[{"given":"Katrin","family":"Druschky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Bleich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Grohmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Burda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helge","family":"Frieling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hillemacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Neyazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"St\u00fcbner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sermin","family":"Toto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2018,8,5]]},"reference":[{"key":"S0924933800008841_bib0005","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-199708040-00005"},{"key":"S0924933800008841_bib0010","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-014-0086-4"},{"key":"S0924933800008841_bib0090","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780120902"},{"key":"S0924933800008841_bib0100","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1995.tb01556.x"},{"key":"S0924933800008841_bib0065","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8635(18)30738-1"},{"key":"S0924933800008841_bib0060","first-page":"11","article-title":"Alopecia\u2014a challenge for dermatologists","volume":"118","author":"Br\u0103ni\u015fteanu","year":"2014","journal-title":"Rev Med Chir Soc Med Nat Iasi"},{"key":"S0924933800008841_bib0050","first-page":"14","article-title":"Clinical toxicity of chemotherapeutic agents: dermatologic toxicity","volume":"9","author":"Dunagin","year":"1982","journal-title":"Semin Oncol"},{"key":"S0924933800008841_bib0020","doi-asserted-by":"publisher","DOI":"10.1016\/S0033-3182(91)72085-9"},{"key":"S0924933800008841_bib0105","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199447020-00008"},{"key":"S0924933800008841_bib0055","first-page":"315","volume-title":"Dermatological signs of internal disease","author":"Sperling","year":"2003"},{"key":"S0924933800008841_bib0095","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1983.tb04607.x"},{"key":"S0924933800008841_bib0030","first-page":"15","article-title":"Androgenetic alopecia","volume":"149","author":"Piraccini","year":"2014","journal-title":"G Ital Dermatol Venereol"},{"key":"S0924933800008841_bib0075","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-013-0419-y"},{"key":"S0924933800008841_bib0155","doi-asserted-by":"publisher","DOI":"10.5455\/bcp.20120719020657"},{"key":"S0924933800008841_bib0025","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-0960.1983.tb00264.x"},{"key":"S0924933800008841_bib0085","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.55.8.1170"},{"key":"S0924933800008841_bib0145","doi-asserted-by":"publisher","DOI":"10.1177\/070674370204700925"},{"key":"S0924933800008841_bib0040","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.04.070"},{"key":"S0924933800008841_bib0110","doi-asserted-by":"publisher","DOI":"10.3109\/10401239609147756"},{"key":"S0924933800008841_bib0080","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.5643.531"},{"key":"S0924933800008841_bib0015","doi-asserted-by":"publisher","DOI":"10.1345\/aph.18346"},{"key":"S0924933800008841_bib0140","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1819.1994.tb03017.x"},{"key":"S0924933800008841_bib0125","first-page":"249","volume-title":"Cutaneous side effects of drugs","author":"Bork","year":"1988"},{"key":"S0924933800008841_bib0135","doi-asserted-by":"publisher","DOI":"10.1002\/hup.470080611"},{"key":"S0924933800008841_bib0045","first-page":"272","article-title":"Diagnosis and management of the hair loss patient","volume":"40","author":"Stroud","year":"1987","journal-title":"Cutis"},{"key":"S0924933800008841_bib0070","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1055\/s-2004-815505","article-title":"The AMSP drug safety program: methods and global results","volume":"37","author":"Grohmann","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"S0924933800008841_bib0130","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(98)00028-7"},{"key":"S0924933800008841_bib0150","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e3280117fff"},{"key":"S0924933800008841_bib0035","doi-asserted-by":"publisher","DOI":"10.3109\/10401230009147085"},{"key":"S0924933800008841_bib0115","first-page":"1132","article-title":"Tolerance to and unwanted effects of valproate sodium","volume":"83","author":"Despland","year":"1994","journal-title":"Schweiz Rundsch Med Prax"},{"key":"S0924933800008841_bib0120","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.143.1.42"}],"container-title":["European Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924933818301615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924933818301615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0924933800008841","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T10:57:47Z","timestamp":1578653867000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0924933800008841\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,5]]},"references-count":31,"alternative-id":["S0924933800008841"],"URL":"https:\/\/doi.org\/10.1016\/j.eurpsy.2018.08.003","relation":{},"ISSN":["0924-9338","1778-3585"],"issn-type":[{"value":"0924-9338","type":"print"},{"value":"1778-3585","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe hair loss associated with psychotropic drugs in psychiatric inpatients\u2014Data from an observational pharmacovigilance program in German-speaking countries","name":"articletitle","label":"Article Title"},{"value":"European Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eurpsy.2018.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}